Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy American Renal Associates (ARA) stocks in Canada

Learn how to easily invest in American Renal Associates stocks.

American Renal Associates is a diagnostics & research business based in the US. American Renal Associates stocks (ARA.US) are listed on the NYSE and all prices are listed in US Dollars. American Renal Associates employs 4,977 staff and has a trailing 12-month revenue of around $814.1 million.

How to buy shares in American Renal Associates

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy American Renal Associates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

American Renal Associates stock price (NYSE:ARA)

Use our graph to track the performance of ARA stocks over time.

American Renal Associates shares at a glance

Information last updated 2021-03-14.
52-week range$11.33 - $11.52
50-day moving average $11.47
200-day moving average $9.70
Wall St. target price$10.00
PE ratio N/A
Dividend yield $1.3 (11.3%)
Earnings per share (TTM) $-0.67

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is American Renal Associates under- or over-valued?

Valuing American Renal Associates stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of American Renal Associates's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

American Renal Associates's PEG ratio

American Renal Associates's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into American Renal Associates's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

American Renal Associates's EBITDA

American Renal Associates's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $113.5 million.

The EBITDA is a measure of a American Renal Associates's overall financial performance and is widely used to measure a its profitability.

American Renal Associates financials

Revenue TTM $814.1 million
Operating margin TTM 9.73%
Gross profit TTM $254.5 million
Return on assets TTM 4.35%
Return on equity TTM 17.51%
Profit margin -1.11%
Book value $-2.50
Market capitalisation $397.9 million

TTM: trailing 12 months

American Renal Associates share dividends

We're not expecting American Renal Associates to pay a dividend over the next 12 months.

American Renal Associates share price volatility

Over the last 12 months, American Renal Associates's shares have ranged in value from as little as $11.33 up to $11.52. A popular way to gauge a stock's volatility is its "beta".

ARA.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while American Renal Associates's is 1.1062. This would suggest that American Renal Associates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

American Renal Associates overview

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts. .

Frequently asked questions

American Renal Associates in the news

There are no recent company news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site